Abstract
Technological advancements in robotics, imaging and stereotactic localization have made extracranial radiosurgery possible. Stereotactic body radiation therapy (SBRT) utilizes specially modified linear accelerators to deliver radiation to precisely defined anatomic targets. Radiation is delivered in one to five fractions at high doses per fraction compared to conventional radiation therapy techniques. SBRT was first utilized to treat lesions of the lungs, liver, pancreas and spine but in recent years, there has been a growing body of literature describing the use of this technique in head and neck cancer amongst others. These studies indicate that the treatment is well-tolerated by patients, and in the setting of recurrent head and neck cancer is similar in efficacy to other non-surgical salvage strategies. Optimization of treatment parameters has led to improvements in tumor control while reducing the already low rates of severe chronic toxicities. The promising results to date suggest that SBRT may play an increasing role in the therapeutic armamentarium in head and neck cancer.
Keywords: Clinical outcome, clinical indications, primary or recurrent head and neck cancer, novel therapy, Stereotactic Body Radiotherapy, review.
Current Cancer Therapy Reviews
Title:Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies
Volume: 10 Issue: 4
Author(s): Jean-Claude M. Rwigema, John A. Vargo, David A. Clump, Robert L. Ferris, James Ohr and Dwight E. Heron
Affiliation:
Keywords: Clinical outcome, clinical indications, primary or recurrent head and neck cancer, novel therapy, Stereotactic Body Radiotherapy, review.
Abstract: Technological advancements in robotics, imaging and stereotactic localization have made extracranial radiosurgery possible. Stereotactic body radiation therapy (SBRT) utilizes specially modified linear accelerators to deliver radiation to precisely defined anatomic targets. Radiation is delivered in one to five fractions at high doses per fraction compared to conventional radiation therapy techniques. SBRT was first utilized to treat lesions of the lungs, liver, pancreas and spine but in recent years, there has been a growing body of literature describing the use of this technique in head and neck cancer amongst others. These studies indicate that the treatment is well-tolerated by patients, and in the setting of recurrent head and neck cancer is similar in efficacy to other non-surgical salvage strategies. Optimization of treatment parameters has led to improvements in tumor control while reducing the already low rates of severe chronic toxicities. The promising results to date suggest that SBRT may play an increasing role in the therapeutic armamentarium in head and neck cancer.
Export Options
About this article
Cite this article as:
Rwigema M. Jean-Claude, Vargo A. John, Clump A. David, Ferris L. Robert, Ohr James and Heron E. Dwight, Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies, Current Cancer Therapy Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/157339471004150407125823
DOI https://dx.doi.org/10.2174/157339471004150407125823 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies
Current Cancer Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents An Environmentally-Benign Synthesis of Spiro-benzo[1,4]diazepines Using Multi Phase Nano-titania as a Highly Efficient Catalyst via MAOS Technique
Current Organic Synthesis Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Pain Biomarkers in Cancer: An Overview
Current Pharmaceutical Design The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology